Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BIOMARKERIGF

Financiado

Cerrado

Identification of Clinically Useful Biomarkers for IGF I Receptor Signalling n C...

Identification of Clinically Useful Biomarkers for IGF I Receptor Signalling n Cancer The Insulin-like Growth Factor I Receptor (IGF-IR) is widely expressed on human tissues and has been shown to promote the growth and invasiveness of cancer cells. It is a potentially important therapeutic target for several major... ver más

31/08/2014

UCC

799K€

Presupuesto del proyecto: 799K€

Líder del proyecto

UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UCC

0.00€ | Lider

ALMAC

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ONCOINTRABODY Targeting common oncogenes with intracellular monobodies 2M€ Cerrado

PDC2022-133537-I00 VALORIZACION DE AGENTES TERAPEUTICOS DIRIGIDOS A RECEPTORES... 150K€ Cerrado

onCOMBINE Towards evidence based combinations of approved and novel ca... 2M€ Cerrado

de-ALARMIN Novel Prognostic Personalized Biomarker and Therapeutic Tar... 150K€ Cerrado

PID2019-106937RB-I00 HIF2 & NFE2L2, UNA APROXIMACION RACIONAL Y OTRA IMPARCIAL PA... 278K€ Cerrado

ROSETTA Deciphering the Role of aberrant glycOSylation in the rEspon... 176K€ Cerrado

Líder del proyecto

UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 799K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Insulin-like Growth Factor I Receptor (IGF-IR) is widely expressed on human tissues and has been shown to promote the growth and invasiveness of cancer cells. It is a potentially important therapeutic target for several major cancers including breast, lung and colon, and has attracted major interest from pharmaceutical companies and clinicians. Currently, at least 70 clinical trials are underway to test several different IGF-IR kinase inhibitors and blocking antibodies. However, unlike some other growth factor receptors the IGF-IR is not amplified or over-expressed in cancer. One of the major challenges to targeting the IGF-IR in cancer is the lack of suitable biomarkers that will a) assess IGF-IR activity in tumours, b) facilitate selection of patients and subsets of tumours that are most likely to respond to inhibitors, and c) monitor responses to IGF-IR inhibition. This programme aims to address this problem by identifying and validating biomarkers for the IGF-IR signalling pathway in cancer. This programme involves a collaboration between researchers at University College Cork who are experts in IGF-I signalling and researchers at Almac Diagnostics who are experts in pharmacogenomic approaches to biomarker discovery in cancer. The research plan will take two complementary approaches: 1) explore the potential of a list of candidate genes that have already been identified in a screen for IGF-IR activity in cancer; and 2) carry out an unbiased genomic screen using a combination of cell models selected as models for IGF-I signalling and proprietary databases that have been collated from different sources, including patient data. The research programme is highly collaborative and includes extensive transfer of knowledge and experience, and exchanges of researchers between the University and Almac. It is anticipated that the results will generate significant interest from scientists, clinicians and the pharmaceutical industry, and have a major impact on an impo

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores